Destiny Pharma PLC (AIM:DEST, OTC:DTTYF) chief executive Neil Clark is stepping down as boss to pursue new challenges.
Dr Debra Barker, a non-executive director of the business, will replace him on an interim basis.
She has held senior positions at Novartis, Polyphor, Roche, GSK and Polyneuron.
Reflecting on Clark's tenure, Destiny chairman Nick Rodgers said: "Neil's contribution to the company over the last six years has been significant.
"Having recently led the exclusive collaboration and co-development agreement for NTCD-M3 with Sebela Pharmaceuticals, raised finance, achieved the publication of landmark XF-73 phase II data, and positive results from the SPOR-COV research, he has decided that it is the right time for him to move on to a fresh challenge.
"He leaves the business well-positioned with a strong balance sheet and a diversified, late-stage pipeline. On behalf of the board, I want to thank Neil for the commitment he has shown in delivering Destiny's strategy over the last six years since he led the IPO of the business in 2017."